Aldeyra Therapeutics Appoints Biotech Finance Veteran Darlene Deptula-Hicks to Board, Chairing Audit Committee

summarizeSummary

Aldeyra Therapeutics appointed Darlene Deptula-Hicks, an experienced biotech CFO, to its board and as Audit Committee Chair, bolstering financial expertise amid recent regulatory setbacks and a class action lawsuit.

check_boxKey Events

• New Director Appointed

  Darlene Deptula-Hicks, a biotech finance veteran with over 30 years of experience, was appointed as a Class III independent director. She has held senior executive and CFO roles, with expertise in IPOs, capital raises, and M&A.

• Audit Committee Chair

  Ms. Deptula-Hicks will serve as Chair of the Audit Committee and has been determined to be an audit committee financial expert, strengthening financial oversight.

• Routine Annual Meeting Results

  Stockholders approved the election of Todd C. Brady as director, ratified BDO USA, P.C. as the independent auditor, and approved executive compensation on an advisory basis. These are standard annual meeting outcomes.

• Director Compensation

  Ms. Deptula-Hicks received an initial stock option grant for 94,313 shares and will receive annual cash fees and additional stock options for her service.

auto_awesomeAnalysis

Aldeyra Therapeutics has appointed Darlene Deptula-Hicks, a seasoned biotech executive with extensive CFO experience in capital raises and M&A, to its Board of Directors and as Chair of the Audit Committee. This appointment strengthens the company's financial oversight and strategic capabilities at a critical time, following a recent FDA Complete Response Letter for its lead drug and a pending class action lawsuit. Her expertise will be valuable as the company navigates its financial runway and explores future strategic options.